Аналитический комплекс биохимических маркеров для доклинической диагностики и профилактики сердечно-сосудистых заболеваний

Благодаря достижениям мировой научной мысли, клинико-диагностические лаборатории, и диагностические центры, получили в распоряжение возможность анализа огромного количества биохимических маркеров различной природы, и их арсенал год от года пополняется. В предлагаемой статье рассматривается комплекс валидных биомаркеров, объединенных с целью биомедицинской доклинической диагностики и профилактики сердечно-сосудистых заболеваний. В качестве обоснования выбора именно этих биохимических маркеров приведены триггерные процессы, лежащие в основе развития сердечно-сосудистой патологии, с которыми ассоциированы избранные биохимические маркеры. Диагностический комплекс составлен на основе принципа “необходимого и достаточного”, с учетом финансовой целесообразности, и возможности измерения избранных маркеров в широкой сети клинико-диагностических центров или лабораторий. Обзор предназначен в помощь клиницистам с целью более детального понимания начальных, доклинических, стадий сердечно-сосудистых заболеваний, как самой распространенной причине смертности населения в России, а также для широкой аудитории, обучающейся или специализирующейся в области кардиологии.

1. Atkinson Jr AJ, Colburn WA, De Gruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989.

2. Gluud C, Gluud LL. Evidence based diagnostics. BMJ. 2005;330(7493):724-6. doi:10.1136/bmj.3307493724.

3. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177-85. doi: 10.1373/clinchem.2009.126706.

4. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-3. doi:10.1016/j.redox.2015.01.002.

5. Zhong S, Li L, Shen X, et al. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radic Biol Med. 2019; S0891-5849(19)30271-0. doi:10.1016/jReview. PubMed PMID: 30946962.

6. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5):S419. PMID: 10539839.

7. Thiele JR, Zeller J, Bannasch H, et al. Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators Inflamm. 2015;372432. doi:10.1155/2015/372432.

8. Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in Cardiovascular Disease. Front Immunol. 2019;10:823. doi:10.3389/fimmu.2019.00823. PubMed PMID: 31057548.

9. Poredos P. C-reactive protein and the risk of cardiovascular morbidity and mortality. Vasa. 2017;46(2):77-8. doi:10.1024/0301-1526/a000602.

10. Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210-4. doi:10.2337/diabetes.52.5.1210.

11. Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, et al. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. J Cell Physiol. 2018;233(11):8508-25. doi:10.1002/jcp.26791.

12. Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3): 19. doi:101007/s00395-019-0722-5.

13. Rupprecht HJ, Blankenberg S, Bickel C, et al. AutoGene Investigators. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001;104(1):25-31. PMID: 11435333.

14. Jolles S, Jordan SC, Orange JS, et al. Immunoglobulins: current understanding and future directions. Clin Exp Immunol. 2014;Suppl 1:163-8. doi:10.1111/cei.12555.

15. Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017;956:511-40. doi:10.1007/5584_2016_90.

16. Della Corte VD, Tuttolomondo A, Pecoraro R, et al. Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr Pharm Des. 2016; 22(30):4658-68. PMID: 27160758.

17. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107(3):398-404. PMID: 12551862.

18. Pokharel DR, Khadka D, Sigdel M, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria. J Diabetes Metab Disord. 2014;13(1):104. doi:10.1186/s40200-014-0104-3.

19. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabetes care. 2005;28(11):2745-9. PMID: 16249550.

20. Hanson RL, Imperatore G, Bennett PH, et al. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51(10):3120-7 PMID: 12351457.

21. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-9. doi:10.1161/01.CIR.0000080897.52664.94.

22. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245-50. doi:10.1161/01.CIR.0000140677.20606.0E.

23. Tao Z, Shi A, Zhao J. Epidemiological Perspectives of Diabetes. Cell Biochem Biophys. 2015;73(1):181-5. doi:10.1007/s12013-015-0598-4.

24. Inoue H. Central insulin-mediated regulation of hepatic glucose production [Review]. Endocr J. 2016;63(1):1-7. doi:10.1507/endocrj.EJ15-0540.

25. Brown AE, Walker M. Genetics of Insulin Resistance and the Metabolic Syndrome. Curr Cardiol Rep. 2016;18(8):75. doi:10.1007/s11886-016-0755-4.

26. Holman GD. Chemical biology probes of mammalian GLUT structure and function. Biochemical J. 2018;475(22):3511-34. doi:10.1042/BCJ20170677.

27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. PMID: 3899825.

28. Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. Methods Mol Biol. 2009;560:221-38, doi:10.1007/978-1-59745-448-3_15.

29. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13(1):47. doi:10.1186/1472-6823-13-47.

30. Перова Н. В., Озерова И. Н., Александрович О. В. и др. Клиническое значение инсулинорезистентности при нормогликемии натощак. Кардиология. 2011;51(8):49-54.

31. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087-92. PMID: 9203442.

32. Helkin A, Stein JJ, Lin S, et al. Dyslipidemia Part 1-Review of Lipid Metabolism and Vascular Cell Physiology. Vasc Endovascular Surg. 2016;50(2):107-18. doi:10.1177/1538574416628654.

33. Rawla P, Sunkara T, Thandra KC, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clinical Journal of Gastroenterology. 2018;11(6):441-8. doi:10.1007/s12328-018-0881-1.

34. Alexopoulos AS, Qamar A, Hutchins K, et al. Triglycerides: Emerging Targets in Diabetes Care? Curr Diab Rep. 2019;19(4):13. doi:10.1007/s11892-019-1136-3. PMID: 30806837.

35. Roubille F, Sultan A, Huet F, et al. Is hypertriglyceridemia atherogenic? La Presse Medicale. 2018;47(9):757-63. doi:10.1016/j.lpm.2018.08.009.

36. Inayat F, Zafar F, Baig AS, et al. Hypertriglyceridemic Pancreatitis Treated with Insulin Therapy: A Comparative Review of 34 Cases. Cureus. 2018;10(10). doi:10.7759/cureus.3501.

37. Mollazadeh H, Carbone F, Montecucco F. Oxidative burden in familial hypercholesterolemia. J Cell Physiol. 2018;233(8):5716-25. doi:10.1002/jcp.26466.

38. Getz G, Reardon C. Apoprotein E and Reverse Cholesterol Transport. Int J Mol Sci. 2018;19(11):3479. doi:10.3390/ijms19113479.

39. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet. 2007;370(9602):1829-39. PMID: 18061058.

40. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257(16):2176-80.

41. Rosenson RS. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict? Arterioscler Thromb Vasc Biol. 2016;36(5):777-82. doi:10.1161/ATVBAHA.116.307024.

42. Chang JC. Hemostasis based on a novel 'two-path unifying theory' and classification of hemostatic disorders. Blood Coagul Fibrinolysis. 2018;29(7):573-84. doi:10.1097/MBC.0000000000000765.

43. Asada Y, Yamashita A, Sato Y, et al. Thrombus Formation and Propagation in the Onset of Cardiovascular Events. J Atheroscler Thromb. 2018;25(8):653-64. doi:10.5551/jat.RV17022.

44. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2):180-90. doi:10.1111/j.1365-2141.2008.07323.x.

45. Krupiczojc MA, Scotton CJ, Chambers RC. Coagulation signaling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol. 2008;40(6-7):1228-37 doi:10.1016/j.biocel.2008.02.026.

46. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17-24. doi:101016/j.blre.2014.09.003.

47. Thiebaut A M, Gauberti M, Ali C, et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurol. 2018;17(12): 1121-32. doi:10.1016/S1474-4422(18)30323-5.

48. Nijenhuis VJ, Brouwer J, Sondergaard L, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019;heartjnl-2018-314313. doi:10.1136/heartjnl-2018-314313.

49. Danesh J, Lewington S, Thompson S G, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-809. doi:10.1001/jama.294.14.1799.

50. Bridge KI, Philippou H, Ariens RA. Clot properties and cardiovascular disease. Thromb Haemost. 2014;112(11):901-8. doi:10.1160/TH14-02-0184.